Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $4M

NEW YORK (GenomeWeb News) – Molecular diagnostics company Biodesix said in a regulatory document that it has raised about $4 million in a private financing.

The company did not respond to requests for comment, but in its Form D filed with the US Securities and Exchange Commission on Tuesday, Biodesix said that the type of securities offered were options, warrants, or other rights to acquire another security; security to be acquired upon the exercise of an option, warrant, or other right to acquire security; and promissory notes that may be converted into Biodesix's equity securities.

It did not identify the investors or say how the financing will be used.

In April 2012, the Boulder, Colo.-based firm raised $8.8 million in a follow-on sale of its Series D preferred shares. It also raised $12 million in a Series D extension in August 2012.

Four months ago, Biodesix said Medicare would cover its VeriStrat proteomic lung cancer test.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.